

RECEIVED
CENTRAL FAX CENTER

DEC 14 2006

REMARKS

This Amendment is submitted to place the present claims in condition for allowance in accordance with the agreement made between Examiner Truong and Applicants' representatives, Kevin B. Laurence and Matthew S. Bethards. Applicants would like to thank Examiner Truong for the personal interview conducted on November 7, 2006. The rejections under 35 U.S.C. §112, first and second paragraphs were discussed. It was agreed that the proposed amendment would overcome those rejections. Furthermore, the Examiner also agreed that the amendments made to claim 1 appeared to overcome the rejections under 35 U.S.C. §102. By this paper, the specification has been amended, as well as claims 1, 14, 17 and 19. Claim 15 has been cancelled.

The specification has been amended to delete particular species from the list of "preferred compounds" beginning on page 5, line 16. The deleted compounds were originally included in error, and are removed from the list of "preferred compounds" because they are not known to meet the definition of "preferred compound" as set forth on page 66, lines 11-12 of the present application.

Claim 1 was amended to return the recitation regarding X^1 to its original form, while clarifying that when X^1 is N, then R^4 is absent. Exemplary support for this amendment can be found in the disclosure of compounds (73) and (74). Claim 1 was also amended to recite "wherein the compound has a Calcium Receptor Inhibitor Assay IC_{50} value of 30 μ M or lower." Exemplary support for this amendment can be found in the Calcium Receptor Inhibitor Assay disclosed on page 64, line 27 to page 66, line 13. IC_{50} values are determined using the assay disclosed. Compounds having an IC_{50} value of greater than 30 μ M were considered inactive. See page 66, lines 11-12.

Claims 14 and 17 were amended to include the subject matter originally found in claim 15, now cancelled. The Examiner agreed that this amendment would overcome the rejections under 35 U.S.C. §112, first and second paragraphs. Claim 19 was amended to delete a species that was included in error.

Page 10 of 11


SaltLake-293594.1 0050821-00005

U.S. Patent Application Serial No. 10/531,161
Amd. and Response dated December 14, 2006

BEST AVAILABLE COPY

Applicants respectfully assert that claims 1-14 and 16-19 are patentable, and request that a timely Notice of Allowance be issued in this case. If there are any remaining issues preventing allowance of the pending claims that may be clarified by telephone, the Examiner is requested to call the undersigned.

Respectfully submitted,



Kevin B. Laurence
Reg. No. 38,219
Attorney for Applicants

Date: December 14, 2006

STOEL RIVES LLP
One Utah Center
201 South Main Street, Suite 1100
Salt Lake City, UT 84111
Telephone: (801) 578-6932
Facsimile: (801) 578-6999

Page 11 of 11

SaltLake-293594.1 0050821-00005

U.S. Patent Application Serial No. 10/531,161
Amd. and Response dated December 14, 2006